During a Case-Based Roundtable® event, Joshua K. Sabari, MD, continued discussion of key outcomes from the MARIPOSA trial and toxicity management in patients with EGFR-mutated non–small cell lung ...

It is likely that in the near future, more comprehensive PGx studies that involved epigenetic factors, such as miRNA, DNA methylation and histone modification, will be the new norm for PGx ...

Hear Daniel, husband of a lung cancer survivor, discuss the importance of comprehensive biomarker testing. EGFR-positive lung cancer patient, Ashley, shares what she would tell a newly diagnosed ...

It shows how adjusting eGFR results for body surface may improve decision results. The National Kidney Foundation published a consensus document that advocates transition to race-free eGFR ...